ArticleInternational journal of endocrinology2026
LncRNA VCAN-AS1 Sponges miR-374c-3p to Promote Proliferation, Invasion, Migration, and EMT in Thyroid Cancer.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA VCAN-AS1 Sponges miR-374c-3p to Promote Proliferation, Invasion, Migration, and EMT in Thyroid Cancer.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer (TC) is the most common endocrine malignancy worldwide, with a rising incidence in recent years. This study investigates the role of long noncoding RNA VCAN-AS1 (lncRNA VCAN-AS1) in TC cells and its underlying mechanism. Methods and Results: LncRNA sequencing and RT-qPCR revealed that VCAN-AS1 expression in clinical TC tissues was significantly higher than in paracancerous tissues. Methods such as CCK-8, cell scratching, Transwell, and Western Blot were employed to assess the impact of VCAN-AS1 on TC cells. Overexpression of VCAN-AS1 promoted TC cell proliferation, migration, and invasion; downregulated the epithelial-mesenchymal transition (EMT)-related protein E-cadherin; and upregulated N-cadherin, vimentin, slug, and snail. Conversely, silencing VCAN-AS1 reversed these effects. Sequencing identified differentially expressed miR-374c-3p in TC cells between the control and VCAN-AS1 overexpression groups, with functional analysis performed using GO and KEGG pathway enrichment. The regulation of miR-374c-3p by VCAN-AS1 was detected by RT-qPCR in TC cells, and dual-luciferase assays confirmed the binding interaction between VCAN-AS1 and miR-374c-3p. VCAN-AS1 competitively binds with miR-374c-3p, and miR-374c-3p overexpression counteracts VCAN-AS1-induced oncogenic effects. In vivo experiments in mice confirmed the results obtained from in vitro experiments. Conclusion: VCAN-AS1 acts as a competing endogenous RNA, driving TC cell proliferation, migration, invasion, and EMT by sponging miR-374c-3p. These findings contribute to a novel theoretical basis for TC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.